, Ronald E. Kleinman, MD b Dietary supplementation with longchain polyunsaturated fatty acids (LCPUFA) for preterm infants has been a matter of intense interest since the early 1990s. The initial clinical studies from that time period demonstrated that adding omega-3 LCPUFA (mainly from marine oils) to the infant formulas of the day resulted in improved visual and retinal outcomes for preterm infants fed the supplemented formulas compared with those fed nonsupplemented formulas. [1] [2] [3] Until that time, formulas intended for preterm infants were devoid of LCPUFA. These and other studies 4 were designed to provide formula-fed preterm infants a dietary exposure to LCPUFA similar to that of the human milk-fed preterm infant; that is, ∼20 mg/kg per day or 0.2% to 0.3% of total fatty acids as docosahexaenoic acid (DHA), which represents the median daily intake of most infants in resource-rich countries. These trials showed that LCPUFA supplementation of preterm infant formulas was safe. They also reported on the efficacy of various short-term outcomes of neural maturity in some subgroups of infants. [1] [2] [3] [4] [5] These findings resulted in the universal supplementation of infant formulas for preterm infants by the year 2000. Thus, current neonatal feeding practices provide premature infants roughly the same dietary intake of LCPUFA regardless of whether they are fed their mother's milk, preterm infant formula, or a combination of both.
However, a re-examination of LCPUFA accumulation rates during the last trimester of pregnancy found that the DHA which would need to be supplied during the neonatal period (∼60 mg/kg per day [.1% total fatty acids as DHA in milk feedings]) surpasses that delivered by current typical feeding practices (∼20 mg/kg per day).
6 Only 2 randomized trials have attempted to meet the physiologic requirement of DHA in the context of randomized controlled trials. 7, 8 Both trials provided human milk to the intervention group supplemented to a concentration of ∼0.85% DHA, and they compared these infants with a control group fed human milk at the standard concentration of ∼0.2% DHA. However, as a result of the supplementation practices in both trials, the full presumed daily requirement for DHA was not achieved until full enteral feeds were achieved and both also ceased supplementation either at discharge from the hospital or at term. Collectively, these trials reported enhanced visual acuity, 9 better problemsolving ability, 7 and less cognitive delay at 18 months' corrected age.
8 These latter outcomes were most pronounced in girls and in infants born weighing ,1250 g. which included 129 infants with a birth weight ,1500 g. Ninety-eight children (45 in the intervention group and 53 in the control group) participated in the 8-year follow-up trial that demonstrated no differences in cognitive function or brain macrostructure as assessed by using magnetic resonance imaging.
10 These The online version of this article, along with updated information and services, is 
